EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors.
Sergeeva OA, Jin G, Sarkar M, Zeiger J, Dhindwal S, Chin SS, Abulizi A, Lai Z, Brown C, DeMaria WG, Ryan D, An X, Karp HJ, Teran E, Yuan C, Klaskin D, Reeve TA, Yu GK, Tam EM, Kaech SM, Preyer M, Matis L, Fine JS, Martomo SA, Myers JS.
Sergeeva OA, et al. Among authors: chin ss.
Proc Natl Acad Sci U S A. 2025 Nov 25;122(47):e2510829122. doi: 10.1073/pnas.2510829122. Epub 2025 Nov 18.
Proc Natl Acad Sci U S A. 2025.
PMID: 41252152
Free PMC article.